n acetyl cysteine glutathione NAC N-Acetyl-L-Cysteine The mechanism of action of

Fried, R

40 , D370D376 (2012)

MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal toxicology shows wide therapeutic window Injection-site reactions reported anecdotally Known interactions Anticoagulants (theoretical, due to angiogenic activity unstudied) Contraindications Active malignancy (theoretical, due to angiogenic mechanism) Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A

At 12 hpi, a single dose of 1 mg kg 1 Rif, alone or with 100 mg kg 1 KL1, was administered

Rather than indicating good health, researchers hypothesize that this elevation is an inadequate compensatory response